{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:31:00Z","timestamp":1780515060290,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.05.012","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T02:19:50Z","timestamp":1747621190000},"page":"e668-e674.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-1539","authenticated-orcid":false,"given":"Ahmed","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-4498","authenticated-orcid":false,"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6809-4608","authenticated-orcid":false,"given":"Meera","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadil","family":"Zureigat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moath","family":"Albliwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1169-563X","authenticated-orcid":false,"given":"Mark Jinan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Nakitandwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-6869","authenticated-orcid":false,"given":"David S.","family":"Bosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Kurish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-9241","authenticated-orcid":false,"given":"Akriti G.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3142-516X","authenticated-orcid":false,"given":"John C","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Balderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-8647","authenticated-orcid":false,"given":"Abhay","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-3614","authenticated-orcid":false,"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-2333","authenticated-orcid":false,"given":"Moaath K.","family":"Mustafa Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10230","key":"10.1016\/j.clml.2025.05.012_bib0001","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.05.012_bib0002","series-title":"Cancer Facts & Figures 2025","year":"2025"},{"issue":"5","key":"10.1016\/j.clml.2025.05.012_bib0003","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.05.012_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.012_bib0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.05.012_bib0006","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/EDBK_280175","article-title":"Recent Advances in Managing Acute Lymphoblastic Leukemia","volume":"40","author":"DeAngelo","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.clml.2025.05.012_bib0007","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.clml.2025.05.012_bib0008","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.05.012_bib0009","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2025.05.012_bib0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.012_bib0011","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.05.012_bib0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.27617","article-title":"Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802","volume":"119","author":"Stock","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.05.012_bib0013","unstructured":"Patel M, C ZE, Ahmed M, Hadil Z, Jinan CM, Joy N, et al. Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center. Leukemia & Lymphoma. 1-6."},{"issue":"8","key":"10.1016\/j.clml.2025.05.012_bib0014","doi-asserted-by":"crossref","first-page":"563","DOI":"10.6004\/jnccn.2024.0051","article-title":"Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clml.2025.05.012_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clml.2025.05.012_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"12","key":"10.1016\/j.clml.2025.05.012_bib0018","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2025.05.012_bib0019","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.clml.2025.05.012_bib0020","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.05.012_bib0021","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.05.012_bib0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000351172","article-title":"Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study","volume":"130","author":"Buyukasik","year":"2013","journal-title":"Acta Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.012_bib0023","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2025.05.012_bib0024","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood.V128.22.3975.3975","article-title":"Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience","volume":"128","author":"Sasaki","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.05.012_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clml.2016.11.002","article-title":"Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis","volume":"17","author":"El-Cheikh","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.05.012_bib0026","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2017.06.010","article-title":"The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience","volume":"60","author":"Alabdulwahab","year":"2017","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.clml.2025.05.012_bib0027","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25229","article-title":"Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens","volume":"93","author":"Siegel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.05.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14381","article-title":"Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study","author":"Zalapa-Soto","year":"2025","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.012_bib0029","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.clml.2025.05.012_bib0030","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.clml.2025.05.012_bib0031","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.05.012_bib0032","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2024-209438","article-title":"Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial","volume":"144","author":"DeAngelo","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:19:13Z","timestamp":1762600753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001739"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}